Jim Palma, Executive Director at TargetCancer Foundation discusses a new clinical trial called TRACK (TargetRare Cancer Knowledge). Supported by Bayer and Foundation Medicine, TRACK provides rare cancer patients with access to genomic testing, personalized treatment recommendations and information via a virtual panel of rare cancer experts. This approach ensures that patients have access to this trial, even if they do not live near a clinical trial site and can socially distance due to COVID-19.
Keith Boettiger, President, Abbott Neuromodulation discusses the company’s new Patient Controller app that is being integrated into their broader NeuroSphere™ Digital Care connected care management platform. Using Apple smartphone-compatible digital health tools, it is designed to optimize care for people living with chronic pain and movement disorders so that they can stay in contact with their treating physician. He also talks about how Abbott is working closely with pain physicians around the country on how to best reopen their practices and keep their patients safe following the COVID-19 shutdown.
Dr. Matthew Smith, MD, Professor of Medicine at Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center discusses final data published in the “New England Journal of Medicine” (Sep 2020) from the Phase III ARAMIS trial for NUBEQA® (darolutamide) plus androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Beto Casellas, CEO of CareCredit, a Synchrony solution, discusses the partnership with Salucro Healthcare Solutions. He talks about the financial implications of COVID-19 on hospitals, health systems and patients. He also talks about managing unplanned out-of-pocket medical expenses.
Mark Campbell, PharmD, Vice President of Clinical Services for RxBenefits, a technology-enabled pharmacy benefits optimizer (PBO), discusses the company’s PBO model and the components behind the model.
Dr. Joslyn Kirby, Associate Professor in the Department of Dermatology at Pennsylvania State University discusses an often misdiagnosed skin condition of hidradentitis suppurativa (HS) and how it is more than just an inflammatory skin disease. She encourages patients and caregivers to advocate for their care and seek out a dermatologist with experience treating HS who can provide an accurate diagnosis and appropriate treatment options.
Dr. Adam Bingaman, Director of Abdominal Organ Transplantation at Methodist Hospital/Specialty and Transplant in San Antonio, TX discusses tips for transplant patients and their caregivers as they navigate the “new normal” environment. He is joined by Dr. Peter Maag, Chairman and Chief Executive Officer for CareDx, the company behind RemoTraC, a remote home-based monitoring system for transplant patients.
Returning guest, Dr. Len Friedland, VP and Director, Scientific Affairs and Public Health Vaccines at GSK discusses the increase in vaccine preventable hepatitis A cases in the US. He explains why it is so important to stay up to date on immunizations, especially during the pandemic.
Dr. Shmuel Shoham, Associate Professor of Medicine at Johns Hopkins University School of Medicine discusses the multi-center, double-blind randomized controlled convalescent blood plasma trials that are currently testing to determine whether giving people antibodies is effective attreating early-stage coronavirus and in preventing those exposed to it from catching the disease. He explains how this research differs from other therapeutics and vaccines under development and why researchers believe it may be promising for COVID-19. He talks about which patients are good candidates for these trials, and what patients can expect if they choose to participate.
Dr. Steve Kanes, CMO and Dr. Jim Doherty, CRO at Sage Therapeutics discuss the three clinical trials, one major depressive disorder (MDD), one postpartum depression (PPD) and one Essential Tremor (ET) that the company was able to advance in spite of the pandemic. They talk about the learnings Sage is leveraging to overcome challenges that span all of brain health from MDD to emerging treatments that tackle executive function and development.